Process for preparing compound coemzyme medicine and its compound coemzyme medicine and clinical use

A technology of coenzyme and yeast cells, applied in the field of medicine, can solve the problems of the scope of influence, inactivation of coenzyme, degradation and destruction, etc.

Active Publication Date: 2006-06-21
北京奥路特生物医药研发有限公司 +2
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, because the original production process used old production processes such as heating to break the wall, vacuum decompression concentration, dialysis, etc., it resulted in the inactivation and degradation of various coenzymes, thus affecting the range of coenzymes and clinical applications.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Process for preparing compound coemzyme medicine and its compound coemzyme medicine and clinical use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Fresh baker's yeast plus 5 times PH4. The cell suspension was refrigerated and centrifuged at 20,000 CPM for 60 minutes to obtain the supernatant; adsorbed by activated carbon, desorbed with 40% ammonia ethanol solution containing 2% ammonia, adjusted the pH of the desorbed solution to 8.0, put it on an Ambrite IRC50 ion exchange column, and used PH8. 5, 0.02M phosphoric acid solution flushing and elution; the eluate is ultrafiltered with an ultrafilter with a molecular weight cut-off of 8000, and the filtrate is concentrated by nanofiltration to remove H 2 O, concentrated to 1 / 10 of the original volume, adjusted to pH 3.5, added 5 times the volume, precipitated with cold acetone at -10°C, collected the precipitate, dissolved in pyrogen-free water, sterilized potting, and freeze-dried.

[0020] Determine the concentration of each organic component, sterilize and freeze-dry.

[0021] CoAs

Embodiment 2

[0023] Add 6 times PH3.0 and 0.03M acetic acid buffer solution to fresh brewer’s yeast, use a high-pressure homogenizer to crush the cells under a pressure of 70Mpa, keep the cell crushing solution below 10°C, and centrifuge at 30,000CPM for 45 minutes at 3°C ​​to obtain a clear liquid; Ultrafiltration with an ultrafiltration membrane with a cut-off molecular weight of 8000; adsorption on activated carbon, analysis with 40% ammonia ethanol containing 3.0% ammonia; adjust the pH of the analysis solution to 7.5, put it on an AmbriteIRC 50 ion exchange column, and wash with pH9.0, 0.01M phosphate buffer The eluate is ultrafiltered through an ultrafiltration membrane with a cut-off molecular weight of 5000; the ultrafiltrate is removed by reverse osmosis 2 0 was concentrated to 1 / 5 of the original volume, adjusted to pH 2.5, and 10 times the volume of cold acetone at -15°C was added, kept overnight at 0°C, and the precipitate was collected the next day. The precipitate was dissolv...

Embodiment 3

[0026] Add 8 times PH4.5, 0.01M acetic acid buffer solution to fresh edible yeast; use a high-pressure homogenizer to break the yeast cells under a pressure of 150Mpa, and keep the broken liquid below 5°C; centrifuge at 0°C at 35,000cpm for 30 minutes Obtain the supernatant; collect the filtrate; adsorb the filtrate with activated carbon, analyze it with 40% ethanol containing 3.5% ammonia; adjust the pH of the solution to 9.0, put it on an AmbriteIRC 50 ion exchange column, and use pH8.0, 0.03M phosphate buffer For elution, the eluate is ultrafiltered through an ultrafiltration membrane with a cut-off molecular weight of 9000, and the ultrafiltrate is concentrated to 1 / 8 of the original volume by reverse osmosis, adjusted to pH 3.0, and 8 times the volume of cold acetone at -20°C is added, and the next day Collect the precipitate. The precipitate was dissolved in pyrogen-free water, the concentration of each component was measured, sterilized, potted, and freeze-dried.

[00...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a preparation method of a compound coenzyme drug, its compound coenzyme drug and its clinical use, belonging to the technical field of medicine. The compound coenzyme drug of the present invention contains coenzyme A (CoA), coenzyme I (NAD), gluten Cystatin (GSH), adenine triphosphate (ATP) is characterized in that, also contains flavin mononucleotide (FMN), flavin adenine dinucleotide (FAD), adenodiphosphate (ADP), adenophosphate ( AMP), adenosylmethionine (SAM). The present invention increases the number of coenzyme substances in the original compound coenzyme drug product from four to nine by changing the existing production process of the compound coenzyme; the compound coenzyme can protect various cells such as liver cells and cardiomyocytes, maintain Or restore its normal metabolism, so that it can be used in clinical treatments such as heart and liver surgery, liver injury recovery, and cell damage recovery caused by radiation or chemotherapy.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a preparation method of a new compound coenzyme drug, a new compound coenzyme drug and a new clinical application. Background technique [0002] In the 1970s, a compound coenzyme freeze-dried powder for injection was developed, which was extracted from yeast (brewer's yeast, edible yeast and Geotrichum candidum), containing coenzyme A (CoA), coenzyme I (NAD), ATP and Natural coenzyme complex preparation of glutathione. It has long been used to treat acute and chronic hepatitis, idiopathic thrombocytopenic purpura, and thrombocytopenia, and can be used as an adjuvant therapy for coronary artery sclerosis, chronic arteritis, myocardial infarction, oliguria, and uremia caused by renal failure. [0003] Yeast is a single-cell eukaryote, and its cells contain various coenzymes necessary for the metabolism (synthesis and decomposition) of biological substances such as sug...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/06A61K38/06A61P1/16A61P31/12A61P7/04A61P9/10A61P13/12A61P39/02A61P43/00
Inventor 郑昌学
Owner 北京奥路特生物医药研发有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap